Read More

On Jan 16, Elevai Labs Inc Entered Into A License Agreement With INmune Bio, Inc.; INmune Granted The Co Certain Worldwide Exclusive And Non-Exclusive License Rights To Develop, Manufacture, And Commercialize INmunes’s EMx Technology

- SEC Filing On January 16, 2023, Elevai Labs, Inc., a Delaware corporation (the "Company"), entered into a License Agreement (the "License Agreement") with INmune Bio, Inc., a Nevada corporation ("INmune"). Under

ELAB

Read More

INmune Bio Inc. Announces Expansion Of Phase II Clinical Trial For Alzheimer’s Disease In Europe; The Company Received A Cash Refund Of ~$2.8M Pursuant To An Australian Research And Development Tax Incentive

The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive.Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB)

INMB